A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age

NCT07365826 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

1390

Enrollment

INDUSTRY

Sponsor class

Conditions

Pneumococcal Vaccines

Interventions

BIOLOGICAL: 31-valent pneumococcal conjugate vaccine
BIOLOGICAL: Seasonal Influenza Vaccine (SIV) (Flublok)
BIOLOGICAL: Placebo

Sponsor

Vaxcyte, Inc.